Kabir A Khan

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 8

Top Topics

Vascular Endothelial Growth Factor

Top Venues

Nature reviews. Clinical oncology

EMBO molecular medicine

NPJ breast cancer

Science immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Hung-Yang Kuo, Kabir A Khan, Robert S Kerbel
Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials. Nature reviews. Clinical oncology 21 (6) (2024)
Hung-Yang Kuo, Kabir A Khan, Robert S Kerbel
Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials. Nature reviews. Clinical oncology 21 (6) (2024)
Hung-Yang Kuo, Kabir A Khan, Robert S Kerbel
Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials. Nature reviews. Clinical oncology (2024)
Elisabeth J M Huijbers, Kabir A Khan, Robert S Kerbel, Arjan W Griffioen
Tumors resurrect an embryonic vascular program to escape immunity. Science immunology 7 (67) (2022)
Kabir A Khan, Florence T H Wu, William Cruz-Munoz, Robert S Kerbel
Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. EMBO molecular medicine 13 (7) (2021)
Kabir A Khan, Robert S Kerbel
A new Tie1 targeted antibody blocks tumor cell extravasation and metastasis. EMBO molecular medicine 12 (6) (2020)
Kabir A Khan, José Luis Ponce de León, Madeleine Benguigui, Ping Xu, Annabelle Chow, William Cruz-Muñoz, Shan Man, Yuval Shaked, Robert S Kerbel
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer. NPJ breast cancer 6 (2020)
Kabir A Khan, Jack L McMurray, Fiyaz Mohammed, Roy Bicknell
C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation. The FEBS journal 286 (17) (2019)